The effect of moboxetinib on squamous cell carcinoma

Mobocertinib/Mobocertinib (Mobocertinib) is a targeted drug for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations. Although mobosertinib primarily targets EGFR exon 20 insertion (EGFRex20ins) driver mutations, it has also been shown to be active against other types of EGFR mutations.

There is currently a lack of large-scale clinical trial data on the efficacy of mobosetinib in squamous cell carcinoma for this specific subtype. Clinical studies of moboxetinib are mainly focused on patients with non-small cell lung cancer caused by EGFR mutations, and these patients are usually patients with the adenocarcinoma subtype. Therefore, before using moboxetinib in patients with squamous cell carcinoma, more studies are needed to evaluate its efficacy in this subtype of lung cancer. For patients with squamous cell carcinoma, the currently commonly used targeted drug is osimertinib, which targets EGFR mutations. Osimertinib has been approved for first-line treatment of squamous cell carcinoma caused by EGFR L858R and exon 19 deletion mutations.

Mobosetinib The original drug is currently on the market in China and has not yet been included in the medical insurance. SpecificationThe price of 40mg*112 pills per box is about 40,000 yuan, which is very expensive.The Hong Kong version of the original drug Specifications40mg*30 pills per box is priced at more than 7,000 yuan (the price may fluctuate due to exchange rates). Generic drugs of Mobotinib have also been put on the market for sale overseas. Its pharmaceutical ingredients are basically the same as those of the original drugs at home and abroad. For example, the production specifications of Laos Pharmaceutical Factory 40mg*120 pills per box may be more than 4,000 yuan (the price may fluctuate due to the exchange rate), and the price is relatively cheap.